Morbidity and mortality in cardiovascular disorders: Impact of reduced heart rate

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 6, Issue 4, 2001, Pages 313-331

  Singh, Bramah N ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; IVABRADINE; METOPROLOL; OXPRENOLOL; PINDOLOL; PRACTOLOL; PROPRANOLOL; SOTALOL; TIMOLOL; UNCLASSIFIED DRUG; ZATEBRADINE;

AGING; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; FOLLOW UP; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; INDUSTRIAL MEDICINE; LIFE EXPECTANCY; PATHOPHYSIOLOGY; POPULATION RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW;

EID: 0035713128     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840100600401     Document Type: Review

References (84)

1. Heart rate and life expectancy
2. The electrocardiogram of the elephant
3. f) in cells isolated from rabbit sinoatrial node
4. Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3[[2-(3,4-dimethoxyphenyl) ethyl]methylimino] propyl] - 2H-3-benzapin-2-on hydrochloride, a new "specific bradycardic agent"
5. Sinus node inhibitors
6. Retarding effect of lowered heart rate on coronary atherosclerosis
7. Propranolol inhibits coronary atherosclerosis in behaviorally predisposed monkeys fed with atherogenic diet
8. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients
9. Minimum heart rate and coronary atherosclerosis: Independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age
10. Why is reduced heart rate beneficial
11. Heart rate as a risk factor for atherosclerosis and cardiovascular mortality
12. Heart rate as a prognostic factor for coronary heart disease and mortality: Findings in three Chicago epidemiologic studies
13. The multifactor primary prevention trial in Göteborg, Sweden
14. Epidemiologic assessment of the role of physical activity and fitness in development of cardiovascular disease. The Framingham Study
15. Heart rate and cardiovascular mortality: The Framingham Study
16. The epidemiology of resting heart rate in a national sample of men and women: Association with hypertension, coronary heart disease, blood pressure, and other cardiovascular risk factors
17. Pulse rate, coronary heart disease, and death: The NHANES I epidemiologic follow-up study
18. Influence of heart rate on mortality among persons with hypertension: The Framingham study
19. Sudden death: The view from Framingham
20. Factors associated with survival to 75 years of age in middle-aged men and women: The Framingham study
21. Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality
22. The relevance of sympathetic activity in the pharmacological treatment of chronic stable angina
23. Reappraisal of heart rate as a risk factor in the general population
24. Is heart rate a risk factor in the general population?
25. Is heart rate a prognostic factor for cardiovascular disease?
26. Heart rate reduction and morbidity and mortality in cardiovascular disorders
27. Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men
28. The relationship between resting heart rate and all-cause cardiovascular and cancer mortality
29. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: The Chicago Heart Association Detection Project in Industry
30. Influence of heart rate on mortality in a French population: Role of age, gender and blood pressure
31. The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight-year follow-up of 3527 male Israeli employees (the CORDIS Study)
32. Prevalence and control of hypertension in a large cohort of occupationally-active Israelis examined during 1985-1987. The CORDIS Study
33. Heart rate and mortality
34. Heart as a therapeutic target in ischemic heart disease
35. Need for revision of the normal limits of resting heart rate
36. Elevated heart rate as a predictor of increased cardiovascular morbidity
37. Heart rate and subsequent blood pressure in young adults. The CARDIA Study
38. The association between heart rate and blood pressure, blood lipids and other cardiovascular risk factors
39. The epidemiology of resting heart rate in a male working population: Association with blood pressure, age, smoking habits and other cardiovascular risk factors
40. Association between salt intake, heart rate, and blood pressure
41. Association between heart rate and other risk factors in a large French population
42. Heart rate as a risk factor in hypertensive individuals. The Italian TensioPulse Study
43. Association between resting heart rate and hypertension treatment in a general population
44. Anthropometric, lifestyle, and metabolic determinants of resting heart rate. A population study
45. Association of average heart rate on 24-hour ambulatory electrocardiograms with the incidence of new coronary events at 48-month follow-up in 1,311 patients (mean age 81 years) with heart disease and sinus rhythm
46. High heart rate. A risk factor for cardiovascular death in elderly men
47. Influence of heart rate on mortality after acute myocardial infarction
48. Effect of timolol on mortality and reinfarction after acute myocardial infarction: Prognostic importance of heart rate at rest
49. Betablockers and sudden cardiac death
50. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period
51. A randomized trial of propranolol in patients with acute myocardial infarction. Mortality results
52. Beta-blockade during myocardial infarction: An overview of randomized trials
53. Antiarrhythmic impact of anti-ischemic, antifailure and other cardiovascular strategies
54. Effect of metoprolol CR/XL in chronic heart failure (MERIT-HF)
55. Beta-adrenergic blockade in chronic heart failure: Principles, progress, and practice
56. B-Adrenergic receptor blockade in chronic heart failure
57. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomized trial
58. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure
59. Comments-beta-blockers: Heart rate reduction a mechanism of benefit
60. Importance of heart rate in determining betablocker efficacy in acute and long-term acute myocardial infarction intervention trials
61. Controlled trial of sotalol for one year after myocardial infarction
62. Pacemaker mechanisms in cardiac tissue
63. Circadian variation in ischemic threshold: A mechanism underlying the circadian variation in ischemic events
64. Importance of beta blockade in the therapy of serious ventricular arrhythmias
65. Advantages of beta-blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention of myocardial infarction
66. Antiarrhythmic drugs: A reorientation in light of recent developments in the control of disorders of cardiac rhythm
67. Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patients with stable angina
68. Trimetazidineinduced enhancement of myocardial glucose utilization in normal and ischaemic myocardial tissue: An evaluation by positron emission tomography
69. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with a beta-blocker or diltiazem
70. A controlled trial with a novel antiischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris
71. Falipamil (AQ-A 39) and UL-FS 49
72. Veratramine, an antagonist to the caridoaccelerator action of epinephrine
73. Comparison of the hemodynamic effects of the selective bradycardic agent UL-FS 49 with those of propranolol during treadmill exercise in dogs
74. A fourth class of antiarrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function
75. Electrophysiological effects of S 16527, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: Comparison with UL-FS 49
76. f of the rabbit sinoatrial node cellas by zatebradine (UL-FR 49)
77. Comparison of AQA 39 and propranolol and placebo anin ischemic heart disease
78. Mechanism of improved regional myocardial dysfunction by bradycardia. Studies on UL-FS 49 in swine
79. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257
80. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells